NCT04099602

Brief Summary

Jaundice (hyperbilirubinemia) which is one of the common causes of repeated hospitalizations in the neonatal period, is a physiological condition seen in 60% of term babies and 80% of premature babies in the first week of life . Premature babies are more susceptible tobilirubin neurotoxicity. Death and severe sequelae due to hyperbilirubinemia can be prevented by early diagnosis and treatment. Massage is one of the applications that can be used to reduce bilirubin levels in newborn infants. Baby massage facilitates bowel movements and bilirubin excretion by reducing enterohepatic circulation. This study was designed as a randomized controlled trial to investigate the effect of massage on bilirubin levels in premature infants.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
64

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Apr 2018

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 6, 2018

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 6, 2019

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 18, 2019

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

September 18, 2019

Completed
5 days until next milestone

First Posted

Study publicly available on registry

September 23, 2019

Completed
Last Updated

September 27, 2019

Status Verified

September 1, 2019

Enrollment Period

1 year

First QC Date

September 18, 2019

Last Update Submit

September 25, 2019

Conditions

Keywords

neonatal jaundicebaby massagetranscutaneous bilirubin levelpremature infant

Outcome Measures

Primary Outcomes (1)

  • Transcutaneous Bilirubin Levels

    bilirubin level mg/dl

    "through study completion, an average of 1 year"

Secondary Outcomes (1)

  • frequency of defecation

    "through study completion, an average of 1 year"

Other Outcomes (1)

  • length of hospital stay

    "through study completion, an average of 1 year"

Study Arms (2)

Massage group

EXPERIMENTAL

Twice a day after the birth of the baby was massaged by the researcher for 5 days. Bilirubin levels were measured twice daily by the transcutaneous bilirubin meter before the morning massage and 2 hours after the evening massage for 5 days. In the morning (between 07:00-09:00 am) and in the evening (between 19:00-21:00 pm) twice a day, 15-20 minutes baby massage was applied.

Other: Baby Massage

Control group

NO INTERVENTION

The control group who were administered standard care and bilirubin levels were measured twice daily by the transcutaneous bilirubin meter for 5 days

Interventions

Received baby massage and bilirubin levels were measured twice daily by the transcutaneous bilirubin meter for 5 days

Massage group

Eligibility Criteria

Age32 Weeks - 38 Months
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • families being voluntary to participate in the study
  • infants being born between 32 and 37 weeks plus 6 days of gestation
  • infants having a birth weight of ≥1500 g
  • infants having a fifth-minute Apgar score of more than seven
  • infant's bilirubin level is not sufficient to require phototherapy
  • the vital signs of the baby are within normal limits
  • the absence of congenital major malformation of the infants
  • the lack of patent ductus arteriosus requiring treatment
  • no proven sepsis diagnosis

You may not qualify if:

  • neonates with disease disrupting skin integrity (epidermolysis bullosa, ichthyosis, collodion baby)
  • need for phototherapy
  • infants with gastrointestinal obstruction and biliary atresia
  • infants with congenital major deformations

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ege University Faculty of Nursing

Izmir, Bornova, 35100, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Jaundice, NeonatalPremature Birth

Condition Hierarchy (Ancestors)

Hyperbilirubinemia, NeonatalInfant, Newborn, DiseasesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesHyperbilirubinemiaPathologic ProcessesPathological Conditions, Signs and SymptomsObstetric Labor, PrematureObstetric Labor ComplicationsPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital Diseases

Study Officials

  • Hatice Bal Yılmaz, Prof.

    Ege University

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: In the study, the investigators were decided that at least 30 premature infants were included in each group considering that losses might occur during data collection. Block randomization method was used to control the selection bias that might arise during the determination of the study groups. In this method, the number and probability of groups are equal in each block. Infants in both groups were randomized to block stratified by sex and gestational week. In the block randomization, blocks are selected randomly and this process is continued until all the subjects to be included in the study are assigned to the groups and the number of subjects in the groups is equalized at the end of this procedure
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

September 18, 2019

First Posted

September 23, 2019

Study Start

April 6, 2018

Primary Completion

April 6, 2019

Study Completion

July 18, 2019

Last Updated

September 27, 2019

Record last verified: 2019-09

Data Sharing

IPD Sharing
Will not share

Locations